Seeking Alpha

Seeking Alpha Portfolio App for iPad

6,868 people get AMRN articles and Market Currents by email alert.

Get email alerts on AMRN »

AMRN

Amarin Corporation PLC

5/23/2013, 11:09 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 22, 2:07 PM After an early 5% pop to the upside, Amarin (AMRN -0.9%) reverses course to trade lower after the company said the USPTO published a notification tied to its combination product of Vascepa and Statin Therapy. The application is part of AMRN's expansive portfolio, which includes 23 patent applications either issued or allowed, and over 30 applications pending in the U.S. 2 Comments [Healthcare, On the Move]
Wednesday, May 22, 6:58 AM The U.S. Patent Office publishes a Notice of Allowance for Amarin's (AMRN) application "intended to protect the [combination of] Vascepa and statin therapy." (PR) 1 Comment [Healthcare]
Friday, May 17, 3:43 PM Shares of Amarin (AMRN -1.1%) rebound somewhat from an earlier dip on news that its Vascepa wasn't in the FDA's Orange Book for April. 5 Comments [Healthcare, On the Move]
Thursday, May 9, 5:43 PM Amarin (AMRN): Q1 EPS of -$0.41 misses by $0.02. (PR) 2 Comments [Earnings, Breaking News, Healthcare]
Tuesday, April 23, 9:15 AM Amarin (AMRN) says the FDA has accepted its supplemental new drug application for Vascepa and set a December 20 target date to complete its regulatory review. The company's seeking approval of the the cholesterol-reducing fish-oil pill as an adjunct to diet for the treatment of high triglycerides with mixed dyslipidemia. Shares +6.2% in pre-market trading. 8 Comments [Healthcare, On the Move]
Tuesday, April 23, 9:10 AM Premarket gainers: MEMS +50%. SCON +46%. NFLX +24%. VECO +14%. COH +12%. ILMN +10%. ARMH +9%. CZR +8%. STM +6%. AMRN +6%.
Losers: IRWD -10%. RSH -7%. IOC -6%. Comment! [On the Move]
Thursday, April 18, 8:53 AM Amarin (AMRN) rises 2.49% premarket after saying the FDA has approved its Supplemental New Drug Application to add Chemport as a supplier of ingredients for Vascepa, AMRN's first approved product. The move comes as AMRN attempts to expand its supply chain and protect Vascepa's commercial potential by "taking advantage of manufacturing barriers to entry." Comment! [Healthcare, On the Move]
Friday, April 12, 12:03 PM Amarin (AMRN -2%) trades lower on reports that Vascepa's exclusivity status isn't in FDA Orange Book update for March. Earlier this week the drug was listed in a report by EvaluatePharma called "The industry's brightest hopes: where are they now?" as the fourth most disappointing drug, having seen lofty expectations of a potential $2B annual market dwindle down to just $505M. 5 Comments [Healthcare, On the Move]
Monday, April 8, 7:25 AM Amarin (AMRN) gains 1.5% premarket after announcing significants reductions in apolipoprotein C-III levels in Phase 3 testing of Vascepa. Apo C-III is thought in inhibit the clearance of triglycerides from the blood. (PR) 1 Comment [Healthcare]
Tuesday, April 2, 11:14 AM MKM Partners' Jon LeCroy is reiterating his Buy rating and $12 price target on Amarin (AMRN +1.8%) following last week's solid Vascepa weekly prescription data. LeCroy notes that if the current growth continues, assuming a wholesale cost of $184 per prescription and a prescription under-reporting rate of 22%, that would imply Q1 Vascepa sales of approximately $2.2M and Q2 of around $11M. So, while the consensus estimates still appear to be slightly high, LeCroy thinks that with stocking, they still could be attainable. 1 Comment [Healthcare, On the Move]
Monday, April 1, 12:47 PM Amarin (AMRN +1%) gets a boost from some positive commentary out of Leerink Swann today, saying that Vascepa's prescription data appears to be tracking well. The firm notes that the largest TRx advance since the drug's launch was recorded last week, and the number of new prescriptions and refills are growing. Looking forward, Leerink thinks the AMRN's ramped-up marketing efforts and moves to obtain Tier 2 reimbursement should further accelerate TRx growth. 1 Comment [Healthcare, On the Move]
Wednesday, March 20, 12:57 PM Amarin (AMRN -0.6%) lags the general market after being being given a less than enthusiastic initiation by analysts at Chardan Capital Markets with a Hold rating and a price target of $8.50 a share. The firm says that the chance for a strategic deal over the near-term is low, and Vascepa faces risks of a tepid debut. 17 Comments [Healthcare]
Thursday, February 28, 5:35 PM Amarin (AMRN): Q4 EPS of -$0.28 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, February 26, 12:00 PM Amarin (AMRN +1%) gains after saying it's submitted a Supplemental New Drug Application with the FDA seeking approval for the marketing and sale of Vascepa capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides with mixed dyslipidemia. The drug is already approved to treat hypertriglyceridemia, and if cleared for the new indication, it will be the only approved prescription omega 3 therapy for cardiovascular health management in this patient population. Comment! [Healthcare]
Tuesday, February 12, 12:55 PM Amarin (AMRN +1.2%) says the USPTO has granted a Notice of Allowance for patent protection of its Vascepa, a prescription grade omega-3 fatty acid that can help reduce triglyceride levels in adults. The issued patent would have a term that expires no earlier than in 2030. Comment! [Healthcare, On the Move]
Friday, January 18, 2:46 PM Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's fish oil pill Vascepa "no unexpired exclusivity," though no NCE decision was made. 4 Comments [Healthcare, On the Move]